GlaxoSmithKline

New company NeRRe Therapeutics created to develop neurokinin antagonists from GSK

Wednesday, December 19, 2012 10:42 AM

NeRRe Therapeutics, a new drug discovery company, has been launched to develop a portfolio of clinical and pre-clinical neurokinin receptor antagonists divested from GlaxoSmithKline (GSK).

More... »

FDA approves GSK's four-strain seasonal influenza vaccine

Monday, December 17, 2012 04:28 PM

The FDA has approved GlaxoSmithKline’s Fluarix Quadrivalent (influenza virus vaccine) for the immunization of adults and children (three years and older) to help prevent disease caused by seasonal influenza virus subtypes A and B contained in the vaccine.

More... »

GSK, Vodafone to help increase childhood vaccination in Mozambique

Wednesday, December 12, 2012 11:44 AM

Global healthcare company GlaxoSmithKline (GSK) has formed a partnership with Vodafone, one of the world's largest mobile communications companies, to harness innovative mobile technology to help vaccinate more children against common infectious diseases in Africa.

More... »

GSK, Fred Hutchinson Cancer Research Center to develop muscular dystrophy therapeutics

Wednesday, December 12, 2012 10:19 AM

Fred Hutchinson Cancer Research Center and global healthcare company GlaxoSmithKline (GSK) have formed a partnership to develop therapeutics to treat an inherited form of muscular dystrophy.

More... »

UT MD Anderson, GSK collaborate on new approach to cancer immune therapy

Friday, December 7, 2012 02:06 PM

The University of Texas MD Anderson Cancer Center and global healthcare company GlaxoSmithKline (GSK) have signed a research collaboration and license agreement to develop new therapeutic antibodies that promote an immune system attack against cancer.

More... »

Geron discontinues GRN100, cuts 43 workers

Wednesday, December 5, 2012 11:08 AM

Geron, a Menlo Park, Calif.-based biopharmaceutical company developing first-in-class therapies for cancer, has discontinued development of GRN1005, its peptide-drug conjugate designed to treat cancers in the brain. Going forward, the company will focus on the development of imetelstat, its telomerase inhibitor, in hematologic myeloid malignancies and in patients with solid tumors that have short telomeres.

More... »

Ampio Pharmaceuticals names Disbrow as COO

Friday, November 30, 2012 11:45 AM

Ampio Pharmaceuticals, a Greenwood Village, Colo.-based biopharmaceutical company developing repurposed drugs and new molecular entities (NMEs) that treat inflammatory diseases, has appointed Josh Disbrow as chief operating officer.

More... »

Chiromics, GSK enter into collaboration

Monday, November 19, 2012 12:09 PM

Chiromics, a drug discovery company, has formed a collaboration with global healthcare company GlaxoSmithKline to discover novel classes of small molecules against certain biological targets.

More... »

Chimerix appoints Michelle Berrey as CMO

Monday, November 19, 2012 10:45 AM

Chimerix, a Durham, N.C.-based biotechnology company developing orally-available antiviral therapeutics, has appointed Michelle Berrey, MD, MPH, as chief medical officer.

More... »

Aptuit and GSK extend strategic partnership

Monday, November 19, 2012 09:50 AM

Aptuit, a pharmaceutical services company, has reached an agreement on a multi-year extension of its strategic partnership with global healthcare company GlaxoSmithKline (GSK) for dedicated drug development work at The Aptuit Center for Drug Discovery & Development in Verona, Italy. The Verona site—formerly known as GSK’s Medicines Research Centre—was acquired by Aptuit from GSK in 2010.

More... »